|Articles|September 1, 2004

Applied Clinical Trials

  • Applied Clinical Trials-09-01-2004

What Do We Know About Clinical Trials?

I've recently reviewed many articles on subject recruitment, retention, and attrition in clinical trials. I have found the same three basic research methods: surveys (by telephone and in person), interviews, and focus groups. The information gathered from the three methods include demographics, willingness to participate, problems experienced in clinical trials, motivations for volunteering, health behaviors, social support, benefit expectations, and understanding of the research project. But such strategies collect only the most superficial data, so we don't know nearly as much about the clinical trial experience as we need to know.

I've recently reviewed many articles on subject recruitment, retention, and attrition in clinical trials. I have found the same three basic research methods: surveys (by telephone and in person), interviews, and focus groups. The information gathered from the three methods include demographics, willingness to participate, problems experienced in clinical trials, motivations for volunteering, health behaviors, social support, benefit expectations, and understanding of the research project. But such strategies collect only the most superficial data, so we don't know nearly as much about the clinical trial experience as we need to know.

In his 2003 book What Customers Think, Harvard professor Gerald Zaltman explains why traditional market research methods such as surveys, interviews, and focus groups—the methods often used to study the clinical trial experience—are of limited effectiveness, and what market researchers should be doing instead. Table 1 summarizes Zaltman's market research myths and market research realities, which I've adapted to the clinical trial experience.

One way to increase our understanding is to consider the recruitment and informed consent process as a marketing and sales presentation, in which prospective subjects offer their bodies and minds in exchange for an experimental drug or device. In this way, they can also be viewed as customers who have to make a buying decision. Do they "buy into" a clinical trial or not? From that perspective, emerging market research (realities) should replace traditional research strategies (myths) so that researchers can better understand the complexities of the clinical trial experience from a discipline that knows how to study customer behavior.

Table 1 Myths and realities in clinical trial research

The 21st century demands that clinical trials be understood using 21st century market research methods. Clinical trials can't be done without subjects, and subjects won't be recruited or retained unless sponsors and researchers are willing to incorporate new research strategies to better understand the complex nature of the clinical trial experience.

Articles in this issue


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.